Determinants of the recommended phase 2 dose of molecular targeted agents
Author:
Affiliation:
1. Princess Margaret Cancer Centre; Drug Development Program; Toronto Ontario Canada
2. Institute of Health Policy Management and Evaluation; University of Toronto; Toronto Ontario Canada
Publisher
Wiley
Subject
Cancer Research,Oncology
Reference23 articles.
1. Dose selection in phase I studies: why we should always go for the top;Sleijfer;J Clin Oncol.,2008
2. Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs;Fontes Jardim;Clin Cancer Res.,2014
3. Clinical benefit in phase-I trials of novel molecularly targeted agents: does dose matter?;Postel-Vinay;Br J Cancer.,2009
4. Dose-response relationship in phase I clinical trials: a European Drug Development Network (EDDN) collaboration study;García;Clin Cancer Res.,2014
5. Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials;Gupta;J Natl Cancer Inst.,2012
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Neoadjuvant Exercise Therapy in Prostate Cancer;JAMA Oncology;2024-07-18
2. Reporting and impact of subsequent cycle toxicities in oncology phase I clinical trials;Clinical Trials;2023-11-14
3. Current studies and future directions for medulloblastoma: A review from the pacific pediatric neuro-oncology consortium (PNOC) disease working group;Neoplasia;2023-01
4. Phase 1a, Decentralized Trial of Neoadjuvant Exercise Therapy in Prostate Cancer;2023
5. Phase 2;Fundamentals of Drug Development;2022-08-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3